TC BioPharm (Holdings) plc American Depositary Shares - TCBP STOCK NEWS

TC Biopharm, a clinical-stage biotechnology company, has announced a strategic collaboration with The University of Texas MD Anderson Cancer Center as of January 17, 2023. This partnership aims to enhance understanding of gamma-delta T cells for cancer treatment over a three-year period. The collaboration will harness MD Anderson's clinical trial infrastructure alongside TC Biopharm's gamma-delta T cell oncology pipeline, focusing on preclinical and clinical studies. The initiative is expected to yield insights that will refine future studies and aid in the development of new cancer therapies, particularly in blood cancers and solid tumors.

TC BioPharm (NASDAQ: TCBP) announced significant developments in its clinical pipeline and financial performance. They have dosed the first three patients in a Phase 2b trial for OmnImmune®, a therapy for Acute Myeloid Leukemia (AML), which showed promising response rates in prior studies. Financially, the company reported a net income of £0.5 million ($0.6 million) for the first half of 2022, a turnaround from a £2.6 million loss in 2021. Cash reserves stand at £6.0 million ($7.3 million), bolstered by a recent PIPE financing of £6.0 million in November 2022.

TC BioPharm (Nasdaq: TCBP) has successfully closed a private placement, raising $7.35 million by issuing 1,470,000 American Depositary Shares (ADSs) at a price of $5.00 per ADS. This includes Series A and Series B warrants, both with an exercise price of $5.00. The funds will be used for general working capital. The offering was conducted under Regulation D, targeting accredited investors. TC BioPharm specializes in allogeneic gamma-delta T cell therapies for cancer treatment and is currently engaged in pivotal clinical trials.

TC BioPharm (Nasdaq: TCBP) announced a private placement agreement for 1,470,000 American Depositary Shares (ADSs) and associated warrants, raising an expected $7.35 million. The purchase price is set at $5.00 per ADS, with Series A and B warrants exercisable at the same price. The closing is anticipated on November 30, 2022, subject to customary conditions. Proceeds will support general working capital. The offering is exclusively for accredited investors under Section 4(a)(2) of the Securities Act, and the Company plans to file registration statements with the SEC for resale of the ADSs.

TC Biopharm has initiated the dosing of three patients in its Phase 2b clinical trial of OmnImmune®, targeting Acute Myeloid Leukemia (AML). This trial includes a safety cohort of five patients, with results expected by the end of 2022. Following this, the study will move to open enrollment in January 2023, aiming to enroll around 37 patients, including those with myelodysplastic syndromes. The trial represents a pivotal step in TC Biopharm's strategy to advance its innovative gamma-delta T cell therapies.

TC BioPharm (NASDAQ: TCBP) has appointed a new Scientific Advisory Board (SAB) to enhance its gamma-delta T cell therapies for cancer treatment. The SAB, which includes experts from leading institutions, will focus on advancing clinical trials and establishing strategic partnerships in cell therapy. CEO Bryan Kobel highlighted the potential for growth in gamma-delta platform therapies. The company is already conducting pivotal trials for its OmnImmune® product, targeting acute myeloid leukemia, leveraging its proprietary CryoTC technology to enhance treatment delivery.

TC BioPharm (NASDAQ: TCBP) announced its management will present at the Dawson James 7th Annual Small Cap Growth Conference and the LD MICRO Main Event XV. These events provide opportunities for one-on-one meetings with institutional investors. The Dawson James conference takes place on October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida, while the LD MICRO event is on October 26, 2022, at the Luxe Sunset Blvd Hotel in Los Angeles, California. TC BioPharm specializes in gamma-delta T cell therapies for cancer, with promising developments in clinical trials.

TC Biopharm (NASDAQ: TCBP) announced that the UK regulatory body MHRA has approved an 18-month extrapolated shelf life for its allogeneic cell therapy product, OmnImmune®. This approval allows the company to store and ship the product for clinical trials and future patient treatments, enhancing operational efficiency and scaling. This milestone underscores TC Biopharm's commitment to advancing gamma-delta T cell therapies in oncology and positions OmnImmune® as a leading 'off-the-shelf' cell therapy. CEO Bryan Kobel highlighted this approval as a validation of the company's ongoing development efforts.

TC Biopharm (Holdings) PLC (NASDAQ: TCBP) announced that CEO Bryan Kobel will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 am. The company is focused on developing allogeneic gamma-delta T cell therapies for cancer treatment and is conducting pivotal clinical trials, including a Phase 2b/3 trial for OmnImmune® in acute myeloid leukemia. A webcast of the presentation will be available on TC BioPharm's Investor Relations page.